Osteoporosis is characterised by a decrease in bone mass and deterioration of the microarchitecture of the bone tissue, and is generally associated with an increased risk of fragility fractures . The treatment of osteoporosis aims to prevent the occurrence of fractures, which essentially is achieved by either inhibiting bone resorption or through anabolic treatments . In 1987, teriparatide (Forteo ® ) -the biologically active fragment of human parathyroid hormone (hPTH) was the first FDA approved anabolic therapy for advanced osteoporosis, improving bone microarchitecture, mineral density, and strength . Since 2017, abaloparatide (a PTH related peptide) is also available for the same indication. However, to achieve the bone forming effect, the dosing pattern of teriparatide is crucial . Continuous exposure to teriparatide causes deleterious bone resorption, thus intermittent administration (once daily) is required for the anabolic effect . Frolik et al. investigated different administration patterns of hPTH and identified that the duration of exposure to hPTH is the main determinator of an anabolic or catabolic response . The exact mechanism by which this occurs is currently unknown, however different theories exist including the desensitisation of the PTH1R receptor during continuous exposure . Since teriparatide is a peptide it is administered parenterally as a once daily subcutaneous injection . The need for repeated and frequent injections leads to poor patient adherence, thus limiting its clinical efficacy .